Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors by Azmi, Asfar S. et al.
www.impactjournals.com/oncotarget/  Oncotarget, May, Vol.2, No 5
Oncotarget 2011; 2:  378 - 392 www.impactjournals.com/oncotarget 378
Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination 
Reveals Biological Synergy in wt-p53 solid tumors
Asfar S. Azmi1, Sanjeev Banerjee1, Shadan Ali1, Zhiwei Wang1, Bin Bao1, Frances W.J. Beck2, 
Main Maitah2, Minsig Choi2, Tony F. Shields2, Philip A. Philip2, Fazlul H. Sarkar1, Ramzi M. 
Mohammad2
1 Department of Pathology, Wayne State University School of Medicine
2 Departments of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan
Correspondence to: Fazlul H Sarkar, email: fsarkar@med.wayne.edu
Correspondence to: Ramzi M. Mohammad, email: mohammar@karmanos.org
Keywords: MDM2 and p53, MI-219, oxaliplatin Network Modeling
Received:  April 28, 2011, Accepted: May 11, 2011, Published: May 16, 2011
Copyright: © Azmi et al.  This is an open-access article distributed under the terms of the Creative Commons Attribution License, which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT:
Earlier we had shown that the MDM2 inhibitor (MI-219) belonging to the spiro-oxindole 
family  can  synergistically  enhance  the  efficacy  of  platinum  chemotherapeutics 
leading to 50% tumor free survival in a genetically complex pancreatic ductal 
adenocarcinoma (PDAC) xenograft model. In this report, we have taken a systems 
and network modeling approach in order to understand central mechanisms 
behind MI219-oxaliplatin synergy with validation in PDAC, colon and breast cancer 
cell  lines.  Microarray  profiling  of  drug  treatments  (MI-219,  oxaliplatin  or  their 
combination) in capan-2 cells reveal a similar unique set of gene alterations that is 
duplicated in other solid tumor cells. As single agent, MI-219 or oxaliplatin induced 
alterations in 48 and 761 genes respectively. The combination treatment resulted 
in 767 gene alterations with emergence of 286 synergy unique genes. Ingenuity 
network modeling of combination and synergy unique genes showed the crucial 
role of five key local networks CREB, CARF, EGR1, NF-kB and E-Cadherin. Compared 
to single agents the combination treatment super induced p53 and p21 confirming 
functional synergy. Further, the network signatures were validated at the protein 
level in all three cell lines. Individually silencing central nodes in these five hubs 
interfered  with  MI-219-oxaliplatin  activity  confirming  their  critical  role  in  aiding 
p53 mediated apoptotic response. We anticipate that our MI219-oxaliplatin network 
blueprints can be clinically translated in the rationale design and application of this 
unique  therapeutic  combination  in  a  genetically  pre-defined  subset  of  patients.
InTRoduCTIon
Network modeling and systems biology are 
important tools that are finding applications in the area 
of  drug  discovery  [1].  This  technology  allows  real-
time  simulation  of  how  biological  molecules  function 
in  coordination  to  achieve  a  particular  outcome, 
consequently providing tremendous power of predicting 
the drug response in terms of the effect of modulating the 
function of a given molecule or pathway [2]. A network 
perspective of drug targets has direct implications in drug 
discovery process since it changes the target entity from a 
single molecule to entire molecular pathways or cellular 
networks. Such technologies are crucial for identifying 
and  understanding  the  mechanisms  of  potential  target 
candidates in complex diseases where core de-regulatory 
networks are still being identified [3]. 
Biological interaction networks have been available 
to the scientific community for more than a decade, but 
only in the last few years has the concept of network 
biology found its application in the field of cancer drug 
discovery.  Despite  its  shortcomings,  the  initial  version 
of  human  interactome  networks  are  now  of  sufficient 
quality  to  provide  clinically  useful  information  [4,5]. Oncotarget 2011; 2:  378 - 392 379 www.impactjournals.com/oncotarget
Such integrated analyses may lead to the identification 
of pathways and help in our understanding of single drug 
mechanism  of  action,  synergy  between  two  drugs,  or 
enhance our knowledge as to how one drug modulates the 
effect of another given drug. Thus far, network analysis 
has  facilitated  the  prediction  of  possible  molecules 
affected by specified perturbations of up and downstream 
targets  by  different  drugs.  Such  predictions  can  be 
applied  to  the  development  of  clinically  relevant  drug 
combinations. This is important for understanding drugs 
that are designed against master regulators such as p53, 
known to regulate a variety of targets and is the focus of 
this study. 
p53 (often considered guardian of genome) [6] is 
found mutated in about 50% of all cancers [7,8]. In the 
remaining 50%, p53 is wild type (wt-p53), however, its 
function is inhibited mainly by the cellular oncoprotein 
MDM2  [9,10].  Therefore,  wt-p53  reactivation  by 
blocking  MDM2-p53  interaction  using  small  molecule 
inhibitors is considered an effective therapeutic strategy 
for the treatment of wt-p53 cancer [11-14]. Over the last 
decade,  many  groups  including  ours  have  extensively 
worked  on  developing  small  molecule  inhibitors  of 
MDM2  (here  MI-219,  developed  in  collaboration  with 
Ascenta  Therapeutics  [15])  and  tested  them  against 
multiple cancers including lymphoma [16], PDAC, colon 
and breast [17,18]. Our laboratory has also investigated 
novel and potent combinations of such MDM2 inhibitors 
with standard chemotherapy and demonstrated synergy 
with platinum drug treatments (but not gemcitabine) that 
resulted is tumor free survival in PDAC xenograft models 
[19].  Such  strong  preclinical  evidence  has  accelerated 
the  development  of  MDM2  inhibitors  towards  clinical 
application [20].
We have found that MI-219 when combined with 
oxaliplatin  can  induce  superior  growth  inhibition  in 
wt-p53  PDAC  [21].  This  synergistic  efficacy  was  not 
restricted to a PDAC tumor models and could be translated 
to  other  wt-p53  solid  tumors.  Although  investigations 
from our laboratory certainly prove the potential of these 
inhibitors against wt-p53 tumors, still, our knowledge of 
the mechanism of action of these inhibitors, especially 
their  combination  synergy  with  platinum  drugs,  is 
incomplete. This is because MDM2 has protein partners 
both upstream and downstream but yet are independent 
of p53 [22] and we are still learning the intricacies of the 
Figure 1: MI-219 synergizes with oxaliplatin leading to enhanced growth inhibition in wt-p53 cancer cells. Figure 1 
A) Three wt-p53 cancer cell lines Capan-2 representing PDAC; HCT116, colon cancer and MCF-7, a breast cancer cell line were seeded 
at a density of 3000 cells per well in 96 well plates. After 24 hrs the media was aspirated and cells were exposed to either MI-219 (0-30 
µM) for Capan-2 or (0-15 µM for MCF-7 and HCT-116); oxaliplatin (0-30 µM) for Capan-2 or (0-15 µM for MCF-7 and HCT-116) or 
combination of MI-219 and Oxaliplatin (multiple concentrations in the ratio of 1:1 for isobologram analysis) for 32 hrs. At the end of the 
treatment period, 20 µL of MTT (Sigma St Louis USA) solution (5 mg/ml PBS) was added to each well and incubated at 37 oC for 2 hrs. 
After the incubation period was over, the media was aspirated and re-fed with 20 µL of DMSO per well following rapid mixing on a plate 
shaker. After 15 minutes of shaking the color developed was read at 595 nm using a ELISA Plate reader (TECAN Durham USA). Figure 
1B) Isobologram analysis of MI-219-oxaliplatin combination treatment using CalcuSyn software a CI<1 indicates synergy and is observed 
in all cell lines.Oncotarget 2011; 2:  378 - 392 380 www.impactjournals.com/oncotarget
p53-MDM2 pathway, its role in tumorigenesis and the 
influence of additional regulatory networks on these two 
multifaceted proteins [23,24]. Recently, we have proposed 
that decoding the complexity of targets associated to both 
p53  and  MDM2  requires  a  network  centric  approach 
considering global interacting proteins partners without 
loosing  key  details  [21,  25].  Such  holistic  approach 
will  help  in  better  understanding  of  MDM2  inhibitor 
mechanism of action either alone or in combination with 
various chemotherapeutic drugs.
In  this  paper,  we  utilized  a  systems  biology  and 
network modeling approach to delineated the underlying 
mechanisms  governing  the  synergy  between  MI-219-
oxaliplatin in PDAC cell line. We proposed and provided 
data to demonstrate that our synergy networks signatures 
could be utilized for rationally designing clinical trials of 
MI-219-oxaliplatin in a genetically pre-defined subset of 
patients with not only PDAC, but also in patients with 
other types of cancer, providing an understanding for a 
more optimal outcome.
ReSulTS
MI-219 and oxaliplatin is a highly potent 
combination in wt-p53 solid tumors
In  order  to  understand  mechanism  of  action  of 
MI-219-oxaliplatin  efficacy  we  first  performed  growth 
inhibition  and  apoptosis  studies  in  wt-p53  Capan-2, 
HCT-116 and MCF-7 cancer cells. As can be seen from 
results  of  Figure  1A,  MI-219-oxaliplatin  treatment 
resulted  in  synergistically  enhanced  growth  inhibition 
in all three types of tumors. Isobologram analysis of the 
combination  treatment  showed  statistically  significant 
synergy (Combination Index CI<1 in all three cell lines 
Figure 1 B). Then, we performed apoptosis assays that 
showed  similar  trend  with  maximal  apoptotic  death 
observed in MI-219-oxaliplatin treatment group (Figure 
2). This combination was also found to be synergistic. We 
also evaluated the inhibitory effect of colony formation 
Figure 2: MI-219-oxaliplatin induces synergistically enhanced apoptosis. [Upper Panel] Capan-2, MCF-7 and HCT-116 cells 
were grown in six well plates and treated with either MI-219 (15 µM) or oxaliplatin (15 µM) or the combination of MI-219 and Oxaliplatin 
(15 µM each) for 32 hrs. At the end of the treatment period, cells were trypsinized washed twice with PBS. The pelleted cells were tested 
for apoptosis using Annexin V FITC apoptosis assay according to the manufacturers guidelines (Biovision CA, USA Cat # K-101-100). 
[Lower Panel] Isobologram analysis of MI-219-oxaliplatin indicates synergy. Oncotarget 2011; 2:  378 - 392 381 www.impactjournals.com/oncotarget
in all the three cell lines. In concordance with our growth 
inhibition  and  apoptosis  results,  MI-219-oxaliplatin 
blocked  clonogenic  capacity  of  the  tested  cell  lines 
(Figure 3). The above multiple assays clearly demonstrate 
a synergistic interaction between the two drugs that leads 
to  enhanced  growth  inhibition  in  three  different  solid 
tumor cell lines. We further evaluated the consequence 
of combination treatment on activation of p53 pathway 
using western blot analysis. As can be seen from results 
of Figure 4, compared to single agent the combination 
treatment resulted in slightly superior p53 and p21 re-
activation. However, in order to prove that this is indeed 
a  biological  synergy,  we  performed  network  modeling 
on microarray obtained from individual and combination 
treatment in the same cells.
Microarray  profile  MI-219-oxaliplatin  indicates 
modulation of unique set of genes
Systems and network modeling considers proteins 
as components of a highly interactive network that cross-
talks with different partners in its vicinity. This technology 
can  also  be  used  to  understand  drug  target  response 
networks  considering  each  perturbation  in  its  entirety 
without loosing key detail. Therefore, in order to delineate 
the mechanism of synergy between MI-219-oxaliplatin, 
microarrays were performed on RNA isolated from single 
agent  or  combination  treatment. As  can  be  seen  from 
results  of  Figure  5A,  each  treatment  (control,  MI-219, 
oxaliplatin and combination color coded) has a unique 
set of associated gene signature. As expected of a targeted 
drug, MI-219 as single agent induced a minimal of 48 
gene alterations (Figure 5B smallest circle). Oxaliplatin, a 
cytotoxic agent that has a well recognized toxicity, altered 
761 genes. The combination treatment resulted in a total 
of 767 gene changes (summarized in supplementary Table 
1). However; of paramount significance is the emergence 
of 286 synergy-unique genes that are not found in either 
single  agent  treatment.  This  sizable  number  of  genes 
restricted to the combination treatment is indicative of a 
true biological synergy between MI-219 and oxaliplatin. 
Furthermore,  our  analysis  shows  that  the  entire  set  of 
genes (24,927) could be pooled into four different groups 
(20,128 non-differentially expressed with low variability; 
4,129 differentially expressed with low variability; 238 
differentially expressed with high variability and 432 non-
differentially expressed with high variability) (Figure 5C). 
Figure 3: MI-219-oxaliplatin suppresses colonogenic potential in different cancer cells. Cells were treated as described in 
Figure 1 and after the incubation was over, cells were plated in 100 mm petri plates in a density of 500-1000 cells depending on colonogenic 
potential. The plates were incubated in low CO2 days at 37°C in a 5% CO2/5% O2/90% N2 incubator. The colonies were stained with 2% 
crystal violet and counted. The surviving fraction was normalized to untreated control cells with respect to clonogenic efficiency.Oncotarget 2011; 2:  378 - 392 382 www.impactjournals.com/oncotarget
Figure 4: MI-219-oxaliplatin super induces p53 compared to single agent treatment. MCF-7 and Capan-2 cells grown in 
100 mm petri plates were exposed to either (i) [Left to Right Lanes] vehicle control; (ii) MI-219 15 µM; (iii) Oxaliplatin 15 µM and (iv) 
combination of MI-219 and Oxaliplatin (15 µM each) for 32 hrs and protein was isolated as described in Methods section. Equal amounts of 
protein were analyzed for p53, MDM2 and p21 by Western Blotting. The membranes were re-probed with β-actin as loading control. Note 







Figure 5: Microarray profiling of MI-219-Oxaliplatin treatment in Capan-2 PDAC cells. [A] Human Illumina HT-12 
microarrays were performed on micro array grade RNA isolated from Capan-2 cells treated with either DMSO; MI-219 (15 µM); oxaliplatin 
(15 µM) or their combination for 16 and 32 hrs. Note: each treatment and time point has a unique set of gene expression profile (here color 
coded). All results represent at least triplicate samples except for oxaliplatin 32 hrs that was run in duplicate. [B] Biological Venn diagram 
showing each treatment induces unique set of gene changes (48 for MI-219 single agent treatment; 727 for oxaliplatin treatment; 767 for 
combination treatment and 286 genes as synergy unique genes. [C] Test for differential expression and variability indicates biomarker of 
response. Dataset of 24927 genes was analyzed in combination 32 hr vs. control 32 hrs. Differential gene expression: Combo vs Control (p 
= 0.01) Red = differentially expressed low variability Orange = differentially expressed high variability (potential biomarker of response). 
All values represent triplicate measurements with p value 0.01. Oncotarget 2011; 2:  378 - 392 383 www.impactjournals.com/oncotarget
Such  a  large  number  of  differentially  expressed  genes 
with high variability are indicative of biomarker of drug 
response.
Meta analysis of the total combination genes using 
Ingenuity  Pathway  Analysis  (IPA)  software  showed 
statistical  enrichment  in  canonical  pathways  (pathways 
include  mitotic  roles  of  polo-like  kinases,  cell  cycle: 
G2/M  DNA  damage  checkpoint  regulation,  steroid 
biosynthesis, ILK signaling, phenylalanine, tyrosine and 
tryptophan  biosynthesis  pathways,  valine,  leucine  and 
isoleucine degradation, hereditary breast cancer signaling 
and calcium induced T-lymphocytes apoptosis (Figure 6). 
However, similar analysis of the synergy- unique genes 
showed  an  entirely  different  set  of  statistical  pathway 
enrichment. In this case, the restricted set of pathways was 
for cancer, gastrointestinal disorder, genetic disorder, cell 
cycle and cell death (Figure 6). These results are a further 
validation of the fact the combination synergy represents 
biologically meaningful pathways and not resultant from 
random set of events.
network modeling of MI-219 mediated changes 
at different time points
In order to understand the mechanism of MI-219 
induced changes on oxaliplatin treatment, we performed 
ingenuity modeling of the microarray datasets at different 
time points. As can be seen from results of Figure 7A, 
the initial response to MI-219 treatment (at 16 hrs) is the 
activation of cell survival genes through NF-κB complex 
formation.  However,  at  later  time  points  (32  hrs),  this 
survival signaling is diminished and we observe emergence 
of multiple de-regulated signaling gene networks that are 
indicative of cell death (Figure 7B). In order to verify 
whether, these genetic events could be captured at the 
functional  level  (protein  expression),  we  performed 
western blot analysis on cellular lysates obtained at the 
two treatment time points. Figure 7C shows that at 16 
hrs p65 (component of NF-κB) is highly expressed while 
secondary hub such as EGR1 is not. However, at 32 hrs, 
p65 expression is diminished while EGR1 is activated. Of 
significance is the fact that the protein expression pattern 
induced by MI-219 in PDAC (Capan-2 cells) could be 
Figure 6: Combination synergy represents biologically meaningful process: Analysis of biologically activated functional 
pathways in combination treatment in (left panel) total combination genes vs. synergy unique genes (right panel). Note: 
enrichment of canonical functional pathways in combination datasets vs. restricted set of pathways in synergy unique datasets. Cutoff range 
was set at 1.7 in the ingenuity pathway analysis systems.Oncotarget 2011; 2:  378 - 392 384 www.impactjournals.com/oncotarget
Figure 7: network modeling and validation of MI-219 single agent treatment at different time points. [A] Ingenuity 
pathway analysis of primary events mediated by MI-219 single agent treatment at 16 hrs showing activation of NF-κB central hub. [B] 
Analysis of MI-219 single agent treatment mediated secondary events at 32 hrs showing de-regulated signaling and activation of secondary 
hub EGR1. Analysis presented in A and B are that of three biological replicates...Oncotarget 2011; 2:  378 - 392 385 www.impactjournals.com/oncotarget
Figure 8: Ingenuity network analysis of total combination genes showing change in information flow in cells undergoing 
apoptosis: e-Cadherin represented by CdH1 anti-tumor module is activated in combination treatment. Red is indicative 
of genes going up and green depicts genes suppressed. All analysis presented are means of three biological replicates. 
Figure 7C: network modeling and validation of MI-219 single agent treatment at different time points. [C] Validation 
of primary and secondary gene changes at the functional level i.e. protein expression. Note activation of NF-κB p65 (p65) at 16 hrs and no 
significant changes in EGR1. However, at 32 hrs, p65 expression is lost and EGR1 hub is activated in all three cell lines. β-actin was used 
as loading control. Blots are representative of three independent experiments.Oncotarget 2011; 2:  378 - 392 386 www.impactjournals.com/oncotarget
replicated in an entirely distinct tumor cell line HCT-116. 
Once we obtained insight of the mechanism/perturbations 
induced by MI-219 as a single agent, we explored that 
changes in combination treatment and are discussed in the 
forthcoming passages.
Change  in  information  flow  upon  combination 
treatment: Towards cell death
Apoptotic cells undergo a rapid change in genetic 
information  directed  towards  de-regulated  signaling 
leading to cell death. To provide evidence for this, our 
analysis of the combination genes at late time point (32 
hrs) showed dramatic changes in information flow that 
led to the activation of the anti-tumor E-Cadherin hub, 
(CDH1  protein)  (Figure  8;  Red  showing  up  regulated 
genes and green showing down regulated genes). This is 
in agreement with earlier studies showing that in addition 
to regulating cell junction, E-Cadherin network responds 
to different stresses leading to apoptotic cell death [26]. 
The second activated hub observed in the 32 hr treatment 
group was the NF-κB complex-CREB axis (Figure 9). This 
was a different expression pattern compared to MI-219 
single agent treatment that showed suppression of NF-kB. 
These data further provide evidence for the uniqueness of 
each treatment signature. Our analysis also showed the 
activation of EGR1 network (Supplementary Figure 1) 
and p53-CDKN2A hub (Supplementary Figure 2) that in 
principle drives optimal p53 activation. The activation of 
multiple hubs driving p53 is indicative of a true synergy 
between MI-219-oxaliplatin and suggests clinical testing 
of this combination would be of benefit to patients with 
wt-p53 solid tumors.
Validation of synergy genes at the functional level
The  changes  in  gene  expression  observed  in  the 
microarray  analysis  of  MI-219-oxaliplatin  combination 
synergy provide inconclusive evidence of the mechanism 
of  action  unless  their  functional/effector  translational 
product  is  validated  at  the  protein  level. Therefore,  in 
order to validate our network findings at the functional 
(or  biological)  level,  we  analyzed  the  protein  product 
of prominent hub genes observed in the synergy using 
western blot analysis. The protein expression analysis was 
performed in PDAC, colon and breast cell lines in order to 
assess whether the uniqueness of the synergy genes could 
be translated to other tumors as well. As can be seen from 
Figure 9: Global changes in gene homeostasis showing activation of nF-kB-CReB axis in synergy unique dataset. 
Triplicate datasets of the synergy unique genes were analyzed using ingenuity pathway analysis software and demonstrated activation of 
NF-kB module in tandem with CREB. Note all genes shown here are up-regulated. Oncotarget 2011; 2:  378 - 392 387 www.impactjournals.com/oncotarget
results of Fig 10, along with the enhancement of p53, 
combination  treatment  enhances  CREBBP,  E-Cadherin 
and CARF protein expression in all the cell lines tested. 
That this was observed in two tumor cells lines distinct 
from PDAC clearly confirms that the observed activity of 
MI-219 and oxaliplatin is not a cell-specific phenomenon. 
These  results  are  of  paramount  significance  since  they 
indicate that MI-219-oxaliplatin combination can become 
an effective for a wide range of wt-p53 tumors and not 
restricted to PDAC. 
siRNA silencing confirms the crucial requirement 
of synergy unique genes in MI-219-oxaliplatin 
combination efficacy
Once we establish the enhancement of CBP300 (a 
CREBBP),  CARF,  E-Cadherin  and  NF-κB-p65  (p65) 
at the protein level, we sought to investigate the effect 
of silencing individual genes and validate their role in 
the  observed  synergy  between  MI-219-oxaliplatin.  We 
individually knocked down the above mentioned genes 
and tested the Capan-2, HCT-116 and MCF-7 cells for 
growth inhibition and apoptosis by MI-219-oxaliplatin. 
First, we analyzed the role of p53 in the observed apoptosis 
by MI-219 and oxaliplatin. As can be seen from results 
of Fig 11, siRNA knockdown of p53 abrogated MI-219-
oxaliplatin mediated growth inhibition (MTT Top Panel) 
and apoptosis (Annexin V FITC Bottom Panel) in all the 
three cell lines. These results proved that p53 is central 
player in the efficacy of MI-219-oxaliplatin. Following 
this,  we  individually  knocked  down  CREBBP,  EGR1, 
CDKN2A (p16) and p65 and found that siRNA silencing 
suppresses  the  efficacy  of  MI-219-Oxaliplatin  in  three 
different cell types (data not shown). Most interestingly, 
silencing  E-Cadherin  exhibited  the  opposite  effect  and 
enhanced  the  potential  of  MI-219-oxaliplatin  (Figure 
12). These results support our previous ingenuity gene 
networks studies (Figure 8) where we found changes in 
information flow in the E-Cadherin hub in response to 
combination treatment. 
dISCuSSIon
In this clinically translatable study, we have, for the 
first time, used integrated network modeling and systems 
biology to delineate the mechanism of synergy between 
MDM2  targeted  small  molecule  drug  (MI-219)  and 
oxaliplatin in wt-p53 solid tumors. Based on these novel 
results, we anticipate that our presented information will 
aid in the clinical design of this potent combination in a 
genetically predefined subset of wt-p53 carrying cancer 
patients and will be a step towards tailored therapy.
Our  laboratory  has  been  focused  on  delineating 
Figure 10: Validation of network genes at the protein level: Capan-2, MCF-7 and HCT-116 cells were seeded in 100 
mm petri dishes at the density of 1 million per plate in 10 ml media. Once the cells achieved 60-70 % confluence, media was 
aspirated and replenished with fresh media containing either vehicle alone of MI-219+Oxaliplatin combination (15µM each). The cells 
were incubated for 32 hrs followed and at the end of the treatment period, cells were harvested, washed twice in PBS followed by extraction 
of protein for western blot analysis. Preparation of cellular lysates, protein concentration determination and SDS-PAGE analysis has been 
previously described (28). Equal amounts of protein were analyzed for p53, E-Cadherin, CARF and CREBBP by Western Blotting. The 
membranes were re-probed with β-actin as loading control. Note that the patterns of gene expression were similar in all three cell lines. Oncotarget 2011; 2:  378 - 392 388 www.impactjournals.com/oncotarget
the molecular mechanisms of action of a potent MDM2 
inhibitor MI-219 in solid tumors. MI-219 is a specific, 
orally  active,  low  molecular  weight  inhibitor,  that 
binds to the p53 binding pocket of MDM2 and disrupts 
the  MDM2-p53  interaction  leading  to  apoptosis  via 
reactivating  wt-p53  in  wt-p53  cancer  cells  [27,28]. 
However, this inhibitor is, by itself, a non genotoxic agent. 
We  are  of  the  opinion  that  for  effective  and  clinically 
beneficial activation of p53, it is logical to combine an 
MDM2 inhibitor with genotoxic drugs that activate p53. 
Indeed, MDM2 inhibitor synergizes with platinum drugs 
leading to 50% tumor free survival in PDAC xenograft 
model [19]. Earlier work by Blagosklonny and group have 
demonstrated that a combination of MDM2 inhibitors and 
DNA-damaging  drugs  super-induce  p53  and  that  was 
considered as a mechanism of synergy [29]. However, 
the precise mechanism of this synergy has not been fully 
characterized  at  the  molecular  level.  Additionally,  a 
number of critical networks including microRNA circuits 
have been shown to crosstalk with p53 family members 
p63 and p73 that ultimately governs therapeutic efficacy 
of drug treatment [30]. Given the complex network of 
interaction  between  MDM2  and  p53  that  ultimately 
governs  apoptosis,  it  is  reasonable  to  predict  that 
analyzing the local network of crucial members may help 
understand and elucidate the cellular response to MI-219. 
Figure 11: siRNA silencing of key hub genes abrogates MI-219-oxaliplatin efficacy. [A] Capan-2, MCF-7 and HCT-116 
cells were grown in 96 well plates (for MTT Top Panel) and 6 well plates (for Annexin V FITC apoptosis Lower Panel). Semi confluent 
cells were treated with either DMSO; control siRNA or p53/CBP/EGR1/p16/p65 siRNAs for 5 hrs in serum free pencillin streptomycin 
free media for 5 hrs. After incubation, siRNA containing media was aspirated and cells were allowed to grow overnight in normal media. 
Following the overnight incubation, cells were exposed to MI-219-oxaliplatin combination for 32 hrs. Annexin V FITC apoptosis analysis 
was performed according to the manufacturer’s guidelines (Biovision CA, USA Cat # K-101-100). [B] siRNA silencing of Cadherin under 
similar experimental conditions. All values [in A and B] represent Mean + S.D of triplicate experiment.Oncotarget 2011; 2:  378 - 392 389 www.impactjournals.com/oncotarget
In the case of MI-219, elucidating important key protein/
pathways will help us in identifying patients who are more 
likely to respond to MI-219 treatment, which will provide 
molecular  guidance  for  conducting  rationally  designed 
and tailored combination trials. 
In  this  report,  we  demonstrated  that  in  MI219-
oxaliplatin  combination  has  far  superior  anticancer 
effects than either agent alone in three wt-p53 yet distinct 
solid  tumors  types  (Pancreatic,  Colon  and  Breast). 
Isobologram analysis of the combination ratios confirmed 
that MI-219 and oxaliplatin work in a synergistic (CI<1 
in  all  cases)  and  not  in  an  additive  manner.  However, 
lack  of  mechanistic  studies  supporting  this  synergistic 
combination in a wide spectrum of tumors suggests that 
further research is necessary. Taking a systems biology 
approach, we investigated whether the observed synergy 
between MI-219 and oxaliplatin is indeed the result of 
orchestrated network of molecular events that drive p53 
reactivation towards enhanced apoptosis. As expected of 
a targeted agent, global analysis of genes from microarray 
profiling showed that MI-219 treatment resulted limited 
set of only 48 gene alterations. On the other hand, the well 
recognized cytotoxic agent oxaliplatin induced alterations 
in a larger number of genes (761 genes). The combination 
of MI-219 with oxaliplatin resulted in 767 genes being 
altered  that  were  not  significantly  related  to  MI-219-
oxaliplatin  synergy. The  most  intriguing  aspect  of  this 
finding is the emergence of 286 synergy-specific unique 
genes that were not found in MI-219 or oxaliplatin single 
treatment group (Fig 2 A). These findings confirm that 
synergy between MI-219 and oxaliplatin emanates from 
a well orchestrated set of specific genetic perturbations. 
This  is  further  supported  by  our  ingenuity  analysis  of 
combination and synergy unique gene pools that showed 
some highly contrasting differences between combination 
events and synergistic events. The synergy unique 287 
genes were pooled into 14 closely knit functional groups 
as demonstrated through the ingenuity pathway system. 
Significantly, in contrast to the enrichment of large set 
of canonical pathways in total combinations genes, the 
specific  synergy-unique  associated  14  networks  were 
restricted  to  cancer,  gastrointestinal  disease,  genetic 
disorder, cell cycle and cell death pathway. 
EGR1  is  well  recognized  to  directly  induce 
the  transcription  of  p53  and  binds  to  p53  forming  a 
cytoplasmic  complex  [31].  Direct  binding  of  the  p53 
promoter by Egr1 was first shown in human melanoma 
A375-C6  cells  during  thapsigargin-induced  apoptosis 
[32]. Studies of the Egr1-null mouse system have revealed 
that Egr1 normally controls p53 expression leading to cell 
cycle arrest and senescence [33]. These cells express little 
or no p53 although the gene is intact. This suggested that 
p53 activation by MDM2 inhibitor as single agent or in 
combination  with  oxaliplatin  could  be  aided  by  EGR1 
co-expression. In line with this, we observed activation 
of  EGR1  network  by  MDM2-oxaliplatin  treatment 
and  this  was  validated  at  the  protein  level  in  PDAC, 
colon and breast cells. Furthermore, siRNA silencing of 
EGR1 abrogated in MI219-oxaliplatin efficacy and thus, 
reaffirmed the critical role of EGR1 in synergy of the two 
drugs.
CREB binding protein (CREBBP) is a large (~300 
KDa) pleiotropic cellular coactivator protein critical to 
the execution of virtually all known cellular programs, 
including  cell  growth,  differentiation,  the  integration 
of  both  signal-dependent  and  -independent  cellular 
responses, and apoptosis. CREBBP and its sister protein 
p300 are highly conserved in multicellular organisms and 
have been shown to have profound effects on somatic 
differentiation during early embryogenesis [34,35]. The 
transcriptional activity of p53, which is tightly linked to 
its tumor suppressor function, appears to depend upon 
efficient recruitment of CREBBP to p53 target promoters. 
Consistent  with  this  observation,  recent  studies  have 
shown that the activation domain of p53 participates in 
CREBBP recruitment [36]. Taken together, these findings 
indicate that CREBBP plays a critical role in supporting 
p53-dependent  transcription  function.  Results  from 
our  network  modeling  also  demonstrated  a  statistical 
enhancement of CREBBP hub and western blotting verified 
this  activation  at  the  protein  level.  Similar  to  EGR1, 
siRNA silencing of CREBBP resulted in diminished MI-
219-oxaliplatin activity in PDAC, colon and breast cells. 
These results again indicate that CREBBP plays a definite 
role in optimizing p53 re-activation by MI219-oxaliplatin. 
MI-219-oxaliplatin  network  analysis  also  showed 
emergence of a driver NF-κB network. NF-κB is a master 
transcriptional regulator that is known to regulate a number 
of critical genes governing normal homeostasis of cell 
[37]. In cancer, activation of NF-κB has been associated 
with poor prognosis and resistance to drug treatment [38]. 
MI-219-oxaliplatin  drug  response  signatures  showed 
that NFκB expression was downregulated and secondary 
networks (EGR1 hub) were activated that drove growth 
inhibition and apoptosis. We also observed constitutive 
activation of the NF-κB-CREBB axis. This points to the 
previously unrecognized role of NF-κB in p53 mediated 
apoptosis.  However,  this  regulatory  network  especially 
in response to MI-219, oxaliplatin or combination is still 
poorly understood and requires further investigation. 
Pharmaceutical strategies to re-activate p53 has been 
a topic of intense research in recent years and a number of 
potent small molecules are either in PhaseI/II or entering 
clinical trial [13]. Instead of rushing these promising MDM2 
inhibitors into the clinic, a comprehensive understanding 
of their mechanism of action is first, absolutely necessary 
and network modeling can aid in this effort. In conclusion, 
we have demonstrated by using network modeling, that 
unique driver networks which play a critical role in MI-
219-oxaliplatin synergy can be identified and functionally 
verified. These synergy networks coerce an orchestrated 
set of events that cumulatively optimize p53 re-activation Oncotarget 2011; 2:  378 - 392 390 www.impactjournals.com/oncotarget
resulting  in  enhanced  growth  inhibitory  and  apoptotic 
effects in different wt-p53 cell lines. The results provide 
strong rationale for the design of novel treatment strategies 
using this highly potent combination in patients carrying 
tumors exhibiting wt-p53.
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MATeRIAl And MeTHodS
Cell culture, experimental reagents and chemicals
Capan-2 (PDAC; wt-p53) cells were purchased from 
American  Type  Culture  Collection  (ATCC).  HCT-116 
(Colon cancer; wt-p53) cells were generously provided 
by  Dr.  Vogelstein’s  group.  MCF-7  (Breast  cancer;  wt-
p53)  cells  were  obtained  Karmanos  Cancer  Institute, 
Detroit Michigan. These cell lines have been tested and 
authenticated  in  our  core  facility,  Applied  Genomics 
Technology Center at Wayne State University, as late as 
March 13, 2009. The method used for testing was short 
tandem repeat (STR) profiling using the PowerPlex® 16 
System from Promega (Madison, WI). Primary antibodies 
for  p53,  EGR1,  CBP300  (a  CREBBP),  E  Cadherin, 
MDM2  and  p21  were  purchased  from  Cell  Signaling 
(Beverly  MA). All  secondary  antibodies were obtained 
from Sigma (St. Louis, MO). MI-219 was synthesized by 
using our previously published methods [39,40]. 
Cell growth inhibition studies by MTT and 
clonogenic assay 
Capan-2, HCT-116 and MCF-7 cells were seeded in a 
96-well culture plate (at a density of 3 x 103 cells per well) 
and treated with different ratios of MI-219 (0-30 µM), 
or oxaliplatin (0-30 µM) or their combination for 32 hrs 
and MTT assay was performed as described earlier [41]. 
The results were plotted as means ± SD of three separate 
experiments using six determinations per experiment for 
each  experimental condition.  Clonogenic  assay  for  cell 
survival on the three cell lines was performed according 
to previously described methods [42]. 
Quantification of apoptosis by Annexin V FITC 
flow cytometry and ELISA
Apoptosis in Capan-2, HCT-116 and MCF-7 cells 
was  determined  using  Annexin  V  FITC  apoptosis  kit 
(Biovision  Research  Products)  and  ELISA  detection 
kit (Roche, Palo Alto, CA) according to manufacturer’s 
protocol and published previously [43]. 
siRnA and transfections
To  study  the  effect  of  MI-219-oxaliplatin 
combination on re-activating p53 in the presence of p53 
siRNA, E-Cadherin siRNA, EGR1 siRNA and p65 siRNA 
and CDKN2A (p16) siRNA, we utilized siRNA silencing 
technology in Capan-2, HCT-116 and MCF-7 cells. The 
respective siRNAs and control siRNA were obtained from 
Cell  Signaling.  Cells were  transfected  with  either  p53 
siRNA, E-Cadherin siRNA, EGR1 siRNA or p65 siRNA 
for 5 hrs using LipofectAMINE 2000 according to the 
manufacturer’s protocol (Cell Signaling). After the siRNA 
treatment period cells were further treated with MI-219-
oxaliplatin combination in 96 well plates for MTT and 6 
well plates for Annexin V FITC assays respectively.
Western blot analysis
Capan-2, HCT-116 and MCF-7 cells were exposed 
to either MI-219, oxaliplatin or their combination for 16 
and 32 hrs followed by extraction of protein for western 
blot  analysis.  Preparation  of  cellular  lysates,  protein 
concentration determination and SDS-PAGE analysis has 
been previously described. [44].
 Microarrays and Gene expression Analysis 
Gene expression networks from Capan-2 cells were 
determined from an analysis of global gene expression 
time series data. Cells were plated so that they reached 
75% confluence after 3 days. At this point cultures were 
treated with either MI-219 (15 µM) or oxaliplatin (15 µM) 
or their combination and RNA was isolated from triplicate 
parallel plated plates at 16 and 32 hours after addition of 
inhibitor. Media was changed the day after plating and 
at the start of treatment. Quantitative measurement and 
the high quality of all mRNA samples were assured by 
analysis with the NanoDrop 1000, Agilent Bioanylizer and 
the Agilent RNA 6000 Nano Kit (Agilent Technologies, 
Waldbronn,  Germany).  Expression  levels  at  each  time 
point  for  each  cell  and  treatment  were  determined  by 
microarray analyses using the Illumina human HT12 array. 
Data were processed for quality control and normalized Oncotarget 2011; 2:  378 - 392 391 www.impactjournals.com/oncotarget
across compared arrays by quantile normalization. Genes 
with 1.7 or greater expression fold-change at any time 
point in the series were included in Ingenuity Pathways 
Analyses.  Cluster  analysis  of  expression  profiles  was 
performed with Bayesian analysis using CAGED software. 
Canonical pathways analysis identified the pathways from 
the  Ingenuity  Pathways  Analysis  library  of  canonical 
pathways  that  were  most  significant  to  the  data  set. 
Molecules from the data set that met the 1.7 fold-change 
cut-off  and  were  associated  with  a  canonical  pathway 
in Ingenuity’s Knowledge Base were considered for the 
analysis.  The  significance  of  the  association  between 
the  data  set  and  the  canonical  pathway  was  measured 
in 2 ways: 1) A ratio of the number of molecules from 
the dataset that map to the pathway divided by the total 
number of molecules that map to the canonical pathway. 
2)  Fisher’s  exact  test  was  used  to  calculate  a  p-value 
determining the probability that the association between 
the  genes  in  the  dataset  and  the  canonical  pathway  is 
explained by chance alone. 
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